M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy PharmaphorumNovo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence.NeuroscienceRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) Pharmaphorum Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence. Neuroscience Read full story Post navigation Previous: Third Circuit Affirms Denial of Stelara Biosimilar InjunctionNext: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Related Stories M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Lilly, Gilead lead pharma’s M&A boom pharminent May 8, 2026 M&A / Deals Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq pharminent May 8, 2026
